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Results: After 52 cycles administered, pts received a median of 2 
cycles of treatment (1-6). All patients except one were considered 
evaluable for toxicity, with the recording of ﬁve episodes of (22%) nau-
sea/vomiting grade 1-2 and one (4%) of asthenia grade 1. Four (17%) 
patients developed anaemia grade 2-3 and neutropenia grade1. Two 
additional patients (9%) had neutropenia grade 2 and one (4%) grade 
V. Among twenty evaluable pts for activity, one (4%) showed partial 
response, seven (29%) stable disease and twelve (50%) progression dis-
ease. Median time to progression and overall survival are 54 (12-210) 
and 60 (12-485) days respectively.
Conclusion: At this time of evaluation, intravenous Topotecan with 
this schedule and dose shows promising activity. The accrual still 
continues until the planned sample size following the Simon Two-stage 
design.
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Background: This Phase II study was conducted to evaluate the ef-
ﬁcacy and toxicity of docetaxel single agent in salvage therapy for 
patients with advanced non-small cell lung cancer (NSCLC) who failed 
to respond or relapsed after the geﬁtinib. 
Methods: Patients with histologically conﬁrmed and progressive 
NSCLC after geﬁtinib were eligible for this study. Performance status 
of 0-1 and adequate organ function were required. Patients were treated 
with docetaxel 75 mg/m(2) intravenously for 30 min repeated every 3 
weeks until disease progression or intolerant toxicity. 
Results: Twenty patients were eligible for this study. The TTP for 
iressa was 12 months. Average 2.9 cycles taxotere were given. Hema-
tologic toxicity was mild and with the major toxicity of anemia and 
peripheral neuropathy. The overall response rate (ORR) was 15% and 
disease control rate was 40%. The median survival time (MST) for all 
patients was 542 days (95% CI, 238.2-845.7), TTP was 3.5 months and 
the 1 year survival was 50.2%. 
Conclusions: Docetaxel appeared to be well tolerated as salvage 
therapy for patients with NSCLC who failed to geﬁitinib. 
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Marked response to a cisplatin/docetaxel/temozolomide 
combination in a heavily pre-treated lung cancer patient with a 
metastatic large cell neuroendocrine tumour.
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Introduction: Large cell neuroendocrine carcinoma (LCNEC) is rare 
and differs from other non-small cell lung carcinomas (NSCLC) in that 
it has a particularly aggressive clinical behaviour with poor prognosis. 
We report a dramatic response in body and brain metastases in a heav-
ily pre-treated LCNEC patient receiving a fourth-line combination of 
cisplatin / docetaxel / temozolomide. 
Case Report: A 52-year-old female initially presented with increasing 
breathlessness and superior vena cava obstruction. Histology showed 
LCNEC. Computed tomography showed bulky mediastinal disease. 
Over the next 6 months she received two lines of chemotherapy [cis-
platin / etoposide (stable disease), followed by carboplatin / paclitaxel 
/ radiotherapy (good partial response)]. She progressed 8 months from 
diagnosis with brain metastases (one 5cm diameter). She had a partial 
response to whole brain radiotherapy, but soon after completion she 
was commenced on geﬁtinib for progressive intraabdominal disease. 
She progressed on geﬁtinib with marked clinical deterioration and mas-
sive radiological progression in mediastinum, liver, adrenal and brain 
(12 months from presentation). After a request for more treatment a cis-
platin, docetaxel and temozolomide triplet combination was adminis-
tered [cisplatin 40mg/m2 iv day 1; docetaxel 25 mg/m2 iv days 1, 8, 15; 
temozolomide 150mg/m2 orally days 1-5, every 4 weeks]. The regimen 
was based on a single previous case report in metastatic NSCLC and 
the patient received four cycles of treatment. An excellent symptomatic 
and radiological response (including the brain metastases) was seen, 
with a marked improvement in her quality of life that enabled her to re-
turn to full activity. Unfortunately the disease started to progress again 
four months later and the patient died 20 months from presentation.
Discussion: LCNEC is a rare tumour. The tumour is traditionally 
considered to fall within the category of poorly differentiated NSCLC. 
However, outcomes are similar to SCLC, including a propensity for 
early brain metastases. This is the second report in the literature on the 
use of this speciﬁc chemotherapy combination in NSCLC and the ﬁrst 
report of this cisplatin / docetaxel / temozolomide regimen in LCNEC. 
This triplet is a well-tolerated novel outpatient combination chemother-
apy regimen that treats both systemic and intracranial disease. 
The growing evidence form case series and phase II trials on the use 
of temozolomide containing regimens in patients with reccurent or 
progressive brain metastases from solid tumours will be reviewed. In 
patients who have failed WBRT palliative care was usually the only 
available management option. For ﬁt patients temozolomide singly or 
preferably in combination may offer a real alternative. 
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Background: Chemotherapy for advanced NSCLC has gained 
widespread acceptance since it was demonstrated that cisplatin-based 
chemotherapy improved survival and quality of life.The aim of this 
study is to evaluate the feasibility in terms of overall survival, response 
rate and toxicity of the cisplatin-vinorelbine in Turkish patients with 
metastatic NSCLC.
Methods: In this prospective study, ECOG performance 0-1, che-
motherapy-naive stage IV NSCLC patients (pts) were treated with 
cisplatin (75 mg/m2, d1, IV) and vinorelbine (30 mg/m2, d1and d8, IV) 
every 21 days until progesion or unacceptable toxicity for a maximum 
of 6 cycles in single center. Tumor responses were evaluated by WHO 
criteia. Survival was calculated with the Kaplan-Meier method. Eight 
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patients were still alive. For these patients, the survival was calculated 
until March 8, 2007. 
Results: Between October 2001 and December 2006, a total of 46 
NSCLC patients were treated. Two patients were not evaluable because 
we could not ﬁnd his data ﬁle. Characteristics of patients were as fol-
lows: Median age 56 years (range 41-72), male 41, female 3 and PS 0 
= 7 / 1 = 37. Histologic diagnosis was adenocarcinoma in 17 patients, 
squamous cell carcinoma in 5 and undifferentiated NSCLC in 22. 
Brain metastasis were present 7 patients (16%) prior starting the treat-
ment. Median number of cycles were 3.0 (range 1-6). In 45 evaluable 
patients, complete responses were seen in 1 patient ( 2.3%), partial 
response in 15 (34.1%) and disease stabilization in 19 ( 43.2%). In total 
of 140 cycles, grade 3-4 neutropenia, grade 3-4 leukopenia and grade 
3-4 anemia occured in 16.5%, 10% and 0.7% respectively. One fatal 
event was observed. The median survival was 285 days (95% CI [172-
397]) and at 1 and 2 years survival were 39% and 9.5%, respectively.
Conclusion: The combination of cisplatin plus vinorelbine is an active 
and tolerable regimen in Turkish patients with metastatic NSCLC.
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Phase II study of docetaxel and carboplatin in elderly patients with 
advanced non-small cell lung cancer: final results
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Background: Single-agent chemotherapy has been considered as 
standard treatment for elderly patients with non-small cell lung cancer 
(NSCLC). However recent subset analyses suggest that platinum-
based combination chemotherapy may be safely administered to the 
elderly with good performance status (PS). We evaluated the efﬁcacy 
and safety of carboplatin and docetaxel in a phase II study of elderly 
patients aged 70 years or older.
Methods: Chemotherapy-naive patients aged ≥70 years with advanced 
NSCLC (IIIB-IV), ECOG performance status (PS) of 0-2, a measurable 
lesion, and adequate organ functions were enrolled. Patients received 
carboplatin (AUC 5) and docetaxel (60 mg/m2) administered on day 
1 every 3 weeks. The primary endpoint was response rate (RR). This 
study, with a planned sample size of 25, had 80% power to support the 
hypothesis that the true RR was >30%, and 5% signiﬁcance to deny the 
hypothesis that the true RR was <10%. 
Results: Between October 2003 and April 2006, 30 elderly patients 
with NSCLC were enrolled in the study and all patients were treated. 
Demographics: M/F 20/10; PS 0/1/2 2/23/5; median age 75 (range 70-
84). Median number of treatment cycles was 3.5. Responses in the 30 
evaluable patients included 1CR; 13PR; for an objective RR of 46.7% 
(95%CI 28.8-64.6%). By January 4, 2007, 21 (70.0%) of 30 patients 
had died. Median follow-up for survival was 8.4 months. The median 
time to tumor progression was 4.4 months, and the median survival was 
9.9 months. The 1-year survival rate was 43.3%.Grade 3/4 hematologic 
toxicities included leukopenia (80.0%), neutropenia (86.7%), anemia 
(16.7%) and thrombocytopenia (3.3%). Non-hematologic toxicities 
were mild with no grade 4 toxicities; grade 3 nausea (10.0%), anorexia 
(30.0%), diarrhea (13.3%), fatigue (6.7%), allergic reaction (6.7%), 
pneumonitis (3.3%), febril neutropenia (16.7%) and infection (10.0%) 
were observed. 
Conclusion: The combination of carboplatin and docetaxel was safe 
and promising for the treatment of chemotherapy-naive elderly patients 
with advanced NSCLC. This regimen warrants further evaluation in a 
phase III trial.
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Outcome of patients with stage III and IV non-small cell lung 
cancer in Marmara University Hospital, Istanbul, Turkey
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Background: Lung Cancer is one of the ﬁve most diagnosed cancers in 
Turkey. Treatment outcomes of 353 patients with advanced or metastat-
ic NSCLC who were treated in Marmara University Oncology Clinics 
between April 1997 and March 2007 were evaluated. 
Methods: All patients were diagnosed histologically or cytologically 
and staged with CAT scans. Patients with WHO performance status 
(PS) 2 and lower received chemotherapy (CT). A platinum analogue 
was used in combination with etoposide, vinorelbine, gemcitabine or 
taxanes as the ﬁrst line treatment in 83% patients. Elderly (65 years and 
older) or patients with poor PS (PS=2) were treated with single agent 
CT. Three to 6 cycles of treatment was administered depending on 
clinical or radiological response. Radiation therapy to primary tumor 
was administered to stage III patients after completion of ﬁrst line CT 
and to symptomatic stage IV patients for palliation. Eligible stage IIIA 
patients (16%) were operated. Second line treatment was offered to 
patients with progressive disease for 3 to 6 cycles. 
Results: Median age was 60 years (range: 29-87) and 80% of pa-
tients were male. Histological subtypes were squamous cell in 33%, 
adenocarcinoma in 35%, NSCLC in 30% and large cell cancer 2%. PS 
was 0 in 53% of the patients. Fifteen percent of the patients were stage 
IIIA, 22% were stage IIIB, and 63% were stage IV. The median number 
of cycles administered was 3. At a median follow-up was 11 months 
(range 1-82), 71% of patients died. Median overall survival (OS) was 
14 months, 1-year and 2-year OS ratios were 54% and 27%, respective-
ly. Median time to progression (TTP) was 5 months; 1-year progres-
sion free survival (PFS) ratio was 16%. Women, patients with stage III 
disease, and PS 0 or 1 lived signiﬁcantly longer (p=0.01, p=0.03, and 
p<0.001, respectively). Age, histology, smoking history or type of CT 
didn’t have any statistically signiﬁcant effect on survival in univari-
ate analysis. Only stage had an impact on OS in multivariate analysis. 
Stage was also the only factor on PFS (p<0.001). 
Conclusions: Advanced staged NSCLC patients has poor prognosis. 
Our results are consistent with the world literature.
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